![]() ![]() Novel imaging biomarkers during ketamine treatment will enable a deeper understanding of the therapeutic mechanisms of action (MoA) and the pathophysiology of TRD. ![]() “The study results will help guide atai’s efforts to discover personalized mental health treatments. The availability of a validated protocol to measure structural plasticity at the neuronal level in the human brain would be a great advancement to the field of neuroplasticity research and may represent a potential tool for drug developers, researchers, and providers as an early biomarker of treatment response and efficacy. The study will identify changes in the brain at baseline, 24-48 hours post-treatment, and 2 weeks after ketamine administration. The main objective of this study will be to develop a novel method to detect neuroplasticity through magnetic resonance imaging (MRI) scans, electroencephalogram (EEG) collection and clinical assessments. The study will utilize a neuroimaging method to identify neuroplasticity biomarkers in patients with treatment-resistant depression (TRD) undergoing intravenous (IV) ketamine treatment. (NASDAQ: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH). 17, 2022 (GLOBE NEWSWIRE) - atai Life Sciences N.V.
0 Comments
Leave a Reply. |